PEPT holds Eli Lilly, Novo Nordisk and smaller peptide makers. REX's Bill Birmingham ties the idea to both GLP-1 growth and the gray market peptide scene online.
Recap by typeshit. Full story at The Daily Upside.
An endocrinologist gives a general explainer on who these weight loss injections may suit and how they work, aimed at people with obesity or constant hunger.
She says certain foods prompt the gut to release GLP1 and PYY, which she credits with fullness and slower digestion. A recipe post, not drug news.
Novo's India head Vikrant Shrotriya gave the timing on October 15. EU advisers also backed a revised Kyinsu label for type 2 diabetes, with a final EC decision pending.
The Darling Ingredients unit says the supplement ingredient concentrates over ten neurosupportive peptides, with clinical trials planned to start in December.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Stanford researchers found that blocking a protein could point toward a shot or pill that regrows cartilage, an idea Forbes compares to GLP-1 drugs.
Loading…